Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Insights from 2023 ASH Annual Meeting
Avatar

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Prednisone for BCR-ABL1+ ALL and Blast Phase CML in Adults"

By Insights from 2023 ASH Annual Meeting FEATURING Marlise R. Luskin
By Insights from 2023 ASH Annual Meeting FEATURING Marlise R. Luskin
194 views
December 20, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Leukemia
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
07:33
ecancer

Epitope Editing Enables Targeted Immunotherapy of AML

Feat. G. Casirati
10:42
ASH 2022 Conference Coverage

Results From the Phase 3 ALPINE Study: Zanubrutinib vs. Ibrutinib in…

Feat. J. Brown
04:14
ecancer

ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for…

Feat. J. Brown
11:05
ASH 2022 Conference Coverage

ASH 2022 Preliminary Safety & Efficacy From the Phase 2 APEX Stu…

Feat. D. DeAngelo
14:22
Dana-Farber Cancer Institute

FLT3 Mutations in AML: What Is the Benefit of Midostaurin for Upfron…

Feat. R. Stone
15:59
Dana-Farber Cancer Institute

What's New in AML: Approach to Relapsed and Refractory Disease

Feat. M. Luskin
12:14
Dana-Farber Cancer Institute

FDA Approval of Duvelisib for CLL

Feat. J. Brown
16:18
Dana-Farber Cancer Institute

What is Clonal Hematopoiesis and Why Does It Matter?

Feat. D. Steensma
05:22
Dana-Farber Cancer Institute

Ask the Experts: How I Treat CLL in 2018 Discussion

Feat. M. Davids
23:36
Dana-Farber Cancer Institute

Approach to Frontline Treatment of CLL in 2018

Feat. M. Davids
12:28
Dana-Farber Cancer Institute

CML Frontline Treatment Choice and Monitoring

Feat. D. DeAngelo
20:53
Dana-Farber Cancer Institute

Advances in the Use of Monoclonal Antibodies for ALL

Feat. D. DeAngelo
75:50
Dana-Farber Cancer Institute

Mapping the Future of Acute Lymphoblastic Leukemia

Feat. D. DeAngelo
11:02
Dana-Farber Cancer Institute

FLT-3 Inhibitors in AML

Feat. R. Stone